Pluri Valuation Multiples

Pluri Overview

About Pluri

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Founded

2001

HQ

Employees

142

Website

pluri-biotech.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $1M

EBITDA: ($22M)

EV

$59M

Valuation Multiples

Multiples.vc

Start free trial

Pluri Financials

Pluri reported last fiscal year revenue of $1M and negative EBITDA of ($22M).

In the same fiscal year, Pluri generated $654K in gross profit, ($22M) in EBITDA losses, and had net loss of ($23M).

Pluri P&L

In the most recent fiscal year, Pluri reported revenue of $1M and EBITDA of ($22M).

Pluri expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pluri Stock Performance

Pluri has current market cap of $36M, and enterprise value of $59M.

Pluri's stock price is $3.62.

Pluri Valuation Multiples

Pluri trades at 43.8x EV/Revenue multiple, and (2.7x) EV/EBITDA.

Pluri Financial Valuation Multiples

As of April 20, 2026, Pluri has market cap of $36M and EV of $59M.

Equity research analysts estimate Pluri's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pluri has a P/E ratio of (1.6x).

Pluri Margins & Growth Rates

Pluri's revenue in the last fiscal year grew by 61%.

Pluri's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Pluri Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Pluri M&A Activity

Pluri acquired XXX companies to date.

Last acquisition by Pluri was on XXXXXXXX, XXXXX. Pluri acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pluri Investment Activity

Pluri invested in XXX companies to date.

Pluri made its latest investment on XXXXXXXX, XXXXX. Pluri invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).